Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims

References

• Achour B, Barber J, Rostami-Hodjegan A. (2014). Expression of hepatic drug-metabolizing cytochrome P450 enzymes and their intercorrelations: a meta-analysis. Drug Metab Dispos 42:1349–56.
   PubMed Web of Science ®Google Scholar
• Barter ZE, Crewe KH, Kenny JR, et al. (2012). What is the contribution of CYP2B6 to bupropion metabolic clearance? Implications for the prediction of CYP2B6 mediated drug-drug interactions. 2014. Available at: https://www.certara.com/wp-content/uploads/Resources/Posters/Barter_2012_ISSX_CYP2B6.pdf
   Google Scholar
• Chen Y, Liu L, Nguyen K, Fretland AJ. (2011). Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Drug Metab Dispos 39:373–82.
   PubMed Web of Science ®Google Scholar
• Court MH, Duan SX, Hesse LM, et al. (2001). Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94:110–9.
   PubMed Web of Science ®Google Scholar
• Crewe HK, Barter ZE, Yeo KR, Rostami-Hodjegan A. (2011). Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. Biopharm Drug Dispos 32:303–18.
   PubMed Web of Science ®Google Scholar
• Emoto C, Iwasaki K. (2007). Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes. Xenobiotica 37:986–99.
   PubMed Web of Science ®Google Scholar
• Erickson DA, Mather G, Trager WF, et al. (1999). Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 27:1488–95.
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Maurer TS, Kish M, et al. (2008). A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation and induction determined in vitro. Drug Metab Dispos 36:1698–708.
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Shebley M, Palamanda J, et al. (2016). Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos 44:1720–30.
   PubMed Web of Science ®Google Scholar
• Faucette SR, Hawke RL, Lecluyse EL, et al. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28:1222–30.
   PubMed Web of Science ®Google Scholar
• Hedrich WD, Hassan HE, Wang H. (2016). Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B 6:413–25.
   PubMed Web of Science ®Google Scholar
• Hidestrand M, Oscarson M, Salonen JS, et al. (2001). CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos 29:1480–4.
   PubMed Web of Science ®Google Scholar
• Huang Z, Roy P, Waxman DJ. (2000). Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59:961–72.
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, et al. (2010). Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92–9.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Stubbert K. (2013). Role of cytochrome P4502B6 in methadone metabolism and clearance. Journal of clinical Pharmacology 53:305–13.
   PubMed Web of Science ®Google Scholar
• Knudsen JB, Bastain W, Sefton CM, et al. (1992). Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 22:579–89.
   PubMed Web of Science ®Google Scholar
• Molnari JC, Myers AL. (2012). Carbonyl reduction of bupropion in human liver. Xenobiotica 42:550–61.
   PubMed Web of Science ®Google Scholar
• Nirogi R, Palacharla RC, Uthukam V, et al. (2015). Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays. Xenobiotica 45:95–106.
   PubMed Web of Science ®Google Scholar
• Obach RS, Cox LM, Tremaine LM. (2005). Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33:262–70.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246–55.
   PubMed Web of Science ®Google Scholar
• Oda Y, Hamaoka N, Hiroi T, et al. (2001). Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 51:281–5.
   PubMed Web of Science ®Google Scholar
• Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 pie. Drug Metab Dispos 34:880–6.
   PubMed Web of Science ®Google Scholar
• Palacharla RC, Uthukam V, Manoharan A, et al. (2017). Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro-in vivo extrapolation of hepatic clearance. Eur J Pharm Sci 1:80–9.
   Web of Science ®Google Scholar
• Peltoniemi MA, Saari TI, Hagelberg NM, et al. (2011). Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther 90:296–302.
   PubMed Web of Science ®Google Scholar
• Proctor NJ, Tucker GT, Rostami-Hodjegan A. (2004). Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151–78.
   PubMed Web of Science ®Google Scholar
• Ramírez J, Innocenti F, Schuetz EG, et al. (2004). CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 32:930–6.
   PubMed Web of Science ®Google Scholar
• Roy P, Tretyakov O, Wright J, Waxman DJ. (1999). Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos 27:1309–18.
   PubMed Web of Science ®Google Scholar
• Sager JE, Price LS, Isoherranen N. (2016). Stereoselective metabolism of bupropion to OH-bupropion, threohydrobupropion, erythrohydrobupropion, and 4'-OH-bupropion in vitro. Drug Metab Dispos 44:1709–19.
   PubMed Web of Science ®Google Scholar
• Salonen JS, Nyman L, Boobis AR, et al. (2003). Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos 31:1093–102.
   PubMed Web of Science ®Google Scholar
• Svensson US, Ashton M. (1999). Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol 48:528–35.
   PubMed Web of Science ®Google Scholar
• Talakad JC, Shah MB, Walker GS, Xiang C, Halpert JR, Dalvie D. (2011). Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4. Drug Metab Dispos. 39:539–50
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Tolonen A, Uusitalo J, et al. (2005). Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 77:553–9.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2007). A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1′,1″-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab Dispos 35:2053–9.
   PubMed Web of Science ®Google Scholar
• Wang H, Tompkins LM. (2008). CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598–610.
   PubMed Web of Science ®Google Scholar
• Ward BA, Gorski JC, Jones DR, et al. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300.
   PubMed Web of Science ®Google Scholar
• Yanagihara Y, Kariya S, Ohtani M, et al. (2001). Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 29:887–90.
   PubMed Web of Science ®Google Scholar
• Yates P, Eng H, Di L, Obach RS. (2012). Statistical methods for analysis of time-dependent inhibition of cytochrome P450 enzymes. Drug Metab Dispos 40:2289–96.
   PubMed Web of Science ®Google Scholar
• Yang J, Liao M, Shou M, et al. (2008). Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates and implications for the prediction of drug interactions. Curr Drug Metab 9:384–93.
   PubMed Web of Science ®Google Scholar
• Yang X, Atkinson K, Di L. (2016). Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method. Drug Metab Dispos 44:460–5.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Klein K. (2013). Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 4:24.
   PubMedGoogle Scholar
• Zientek MA, Youdim K. (2015). Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes. Drug Metab Dispos 43:163–81.
   PubMed Web of Science ®Google Scholar